HOOK Logo

HOOKIPA Pharma Inc. (HOOK) 

NASDAQ
Market Cap
$24.52M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
695 of 966
Rank in Industry
388 of 554

Largest Insider Buys in Sector

HOOK Stock Price History Chart

HOOK Stock Performance

About HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Insider Activity of HOOKIPA Pharma Inc.

Over the last 12 months, insiders at HOOKIPA Pharma Inc. have bought $0 and sold $0 worth of HOOKIPA Pharma Inc. stock.

On average, over the past 5 years, insiders at HOOKIPA Pharma Inc. have bought $38,445 and sold $3.92M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,000 shares for transaction amount of $5,075 was made by Kandera Reinhard (Chief Financial Officer) on 2023‑08‑21.

List of Insider Buy and Sell Transactions, HOOKIPA Pharma Inc.

2023-08-21PurchaseChief Financial Officer
7,000
0.0091%
$0.72$5,075-7.79%
2023-08-16PurchaseChief Financial Officer
8,000
0.0103%
$0.71$5,712-5.67%
2023-07-11PurchaseChief Executive Officer
5,000
0.007%
$0.83$4,142-14.57%
2023-07-07PurchaseChief Executive Officer
5,000
0.0068%
$0.81$4,050-14.50%
2023-07-05PurchaseChief Executive Officer
5,000
0.0071%
$0.89$4,450-18.79%
2023-07-03PurchaseChief Executive Officer
5,000
0.0072%
$0.89$4,456-16.94%
2023-06-30PurchaseChief Financial Officer
12,000
0.0166%
$0.88$10,560-19.15%
2021-12-21SaleChief Medical Officer
14,949
0.0457%
$2.49$37,223-37.90%
2021-04-21Sale10 percent owner
328,620
0.9448%
$11.60$3.81M-58.05%
2021-03-29Sale10 percent owner
36,829
0.1234%
$13.67$503,570-54.96%
2021-03-26Sale10 percent owner
35,171
0.1167%
$13.69$481,642-54.91%
2021-03-25Sale10 percent owner
28,546
0.093%
$13.12$374,569-53.55%
2021-03-24Sale10 percent owner
52,690
0.1841%
$13.70$721,616-52.05%
2021-03-23Sale10 percent owner
40,000
0.1374%
$13.91$556,476-53.53%
2021-03-22Sale10 percent owner
40,534
0.1369%
$14.54$589,263-55.71%
2021-03-19Sale10 percent owner
166,230
0.5544%
$14.60$2.43M-56.39%
2020-12-17SaleChief Medical Officer
27,979
0.1031%
$11.74$328,343-20.23%
2020-12-16SaleChief Medical Officer
380
0.0014%
$11.70$4,446-18.84%
2020-10-02Sale10 percent owner
300
0.0011%
$10.00$3,000+13.55%
2020-09-15Sale10 percent owner
41,597
0.1949%
$12.61$524,477+5.48%

Insider Historical Profitability

<0.0001%
SOFINNOVA CAPITAL VI FCPR10 percent owner
3177574
32.9111%
$2.54112<0.0001%
Forbion Capital Fund II Cooperatief U.A.10 percent owner
2494173
25.8329%
$2.5410<0.0001%
BAKER BROS. ADVISORS LP
820729
8.5005%
$2.5410<0.0001%
Matushansky IgorChief Medical Officer
80178
0.8304%
$2.5406
Aldag JornChief Executive Officer
71952
0.7452%
$2.5440<0.0001%
Kandera ReinhardChief Financial Officer
43092
0.4463%
$2.5430<0.0001%
Lilja AndersSr. VP, Technical Development
0
0%
$2.5401
Orlinger KlausSr. VP, Research
0
0%
$2.5403

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$5.79B82.148.13M0%+$041.56
Artal Group S A$4.03B57.275.67M0%+$017.63
Tupelo Capital Management LLC$3.93B55.765.52M0%+$096.35
Ecor1 Capital Llc$3.27B46.444.6M0%+$022.96
Fidelity Investments$2.39B33.943.36M0%+$00.16
The Vanguard Group$1.51B21.412.12M+0.17%+$2.57M0.03
Morgan Stanley$882.93M12.531.24M+4.73%+$39.87M0.07
Redmile Group$757.4M10.751.06M0%+$07.73
Acadian Asset Management$627,000.008.92882,262+85.84%+$289,622.09<0.01
Geode Capital Management$473.33M6.72664,610+13.49%+$56.27M0.04
Ikarian Capital LLC$377.91M5.36530,7760%+$051.95
BlackRock$205.98M2.92289,293-1.69%-$3.55M<0.01
Renaissance Technologies$156,000.002.21218,446+15.8%+$21,281.23<0.0001
Royal Bank of Canada$150M2.13210,297-4.55%-$7.16M0.04
Susquehanna International Group$127.66M1.81179,295New+$127.66M0.13
State Street$114.06M1.62160,1900%+$00.01
Northern Trust$111.66M1.59156,830+41.3%+$32.64M0.02
Boothbay Fund Management LLC$83.8M1.19117,6950%+$02.71
Two Sigma$67.47M0.9694,759+491.65%+$56.06M0.1
Bridgeway Capital Management$62.3M0.8887,5000%+$00.89
Prudential Financial$45.99M0.6564,600New+$45.99M0.07
Xtx Topco Ltd$43.51M0.6261,109-42.22%-$31.79M1.06
Tyler Stone Wealth Management$33.57M0.4847,150+21.21%+$5.87M13.74
Virtu Financial Llc$31,000.000.4443,021New+$31,000.00<0.01
Millennium Management LLC$29.32M0.4241,173-28.56%-$11.72M0.02
Charles Schwab$25.84M0.3736,2850%+$00.01
Two Sigma Advisers LP$25.35M0.3635,600New+$25.35M0.04
Hrt Financial Llc$24,000.000.3534,870New+$24,000.00<0.0001
Jane Street Capital$18.51M0.2626,002New+$18.51M0.02
Beacon Pointe Advisors Llc$16.66M0.2423,4000%+$00.19
Apella Capital, LLC$16.64M0.219,7830%+$01.18
Group One Trading$12.39M0.1817,4040%+$00.16
International Assets Investment Management Llc$10.13M0.1414,0000%+$00.03
UBS$8.84M0.1312,408+112.43%+$4.68M<0.01
Tower Research Capital$7.44M0.1110,451+8.51%+$583,831.210.07
Bank of America$4.56M0.076,405-0.73%-$33,468.70<0.0001
Advisor Group Holdings Inc$2.85M0.044,0000%+$00.01
Wells Fargo$390,000.000.01548+1.48%+$5,693.43<0.0001
Northwestern Mutual Wealth Management Co$71,000.00<0.01100New+$71,000.00<0.0001
Citigroup$53,000.00<0.01740%+$0<0.0001
JPMorgan Chase$10,000.00<0.01140%+$0<0.0001
Truvestments Capital Llc$18,000.00<0.0125New+$18,000.000.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.